Press Releases

 
Press Releases
  Date Title and Summary View
May 12, 2014
Santa Monica, CA – May 12, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Jeffrey S. Wiezorek, M.D., M.S., to the newly created position of Vice President, ...
Apr 29, 2014
Santa Monica, CA – April 28, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the completion of a $50 million mezzanine private financing of convertible notes.  Participan...
Apr 14, 2014
Santa Monica, CA – April 14, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Ms. Cynthia M. Butitta has been appointed its Chief Operating Officer in addition to serving i...
Apr 11, 2014
Santa Monica, CA – April 11, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the appointment of Jonathan M. Peacock, former Chief Financial Officer of Amgen, to the Company's B...
Apr 2, 2014
Santa Monica, CA – April 2, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Arie Belldegrun, M.D., FACS, as President and Chief Executive Officer.  Dr. Belldegrun, who ...
Mar 31, 2014
Los Angeles, CA – March 31, 2014 – Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation f...
Jan 17, 2014
LOS ANGELES, Jan. 17, 2014 -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Rizwana F. Sproule, Ph.D., to...
Jan 9, 2014
New York, Jan. 9, 2014 -- NeoStem, Inc. (NASDAQ:NBS) and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), announced today the execution of a Services Agreement with Kite Pharma, Inc., under which PCT will provide cell therapy process development and manufacturing services for Kite Pharma’s lead engineered Autologous T...
Jan 8, 2014
Los Angeles, CA – January 8, 2014 – Kite Pharma Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Offic...
Dec 7, 2013
At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.  These studies were performed in close co...
Page: FirstPrevious ...
18
NextLast
= add release to Briefcase